68
Views
5
CrossRef citations to date
0
Altmetric
ORIGINAL ARTICLEImaging, Diagnosis, Prognosis

Detection of Serum Anti-p53 Antibodies from Patients with Ovarian Cancer in China: Correlation to Clinical Parameters

, , , , &
Pages 563-568 | Published online: 11 Jun 2009

REFERENCES

  • Wingo P. A., Tong T., Bolden S. Cancer statistics, 1995. C.A. Cancer. J. Clin. 1995; 45: 8–30
  • Chen P. L., Chen Y. M., Bookstein R., Lee W. H. Genetic mechanisms of tumor suppression by the human p53 gene. Science 1990; 1576–1580
  • Davidoff A. M., Iglehart J. D., Marks J. R. Immune response to p53 is dependent upon p53/HSP70 complexes in breast cancers. Proc Natl Acad Sci USA 1992; 89(8)3439–3442
  • Crawford L. V., Pim D. C., Bulbrook R. D. Detection of antibodies against the cellular protein p53 in sera of patients with breast cancer. Int J Cancer 1982; 30(4)403–408
  • Angelopoulou K., Diamandis E. P., Sutherland D. J., Kellen J. A., Bunting P. S. Prevalence of serum antibodies against the p53 tumor suppressor gene protein in various cancers. Int J Cancer 1994; 58(4)480–487
  • Soussi T. p53 Antibodies in the sera of patients with various types of cancer: a review. Cancer Res. 2000; 60(7)1777–1788
  • Goodell V., Salazar L. G., Urban N., Drescher C. W., Gray H., Swensen R E, McIntosh M W, Disis M L. Antibody immunity to the p53 oncogenic protein is a prognostic indicator in ovarian cancer. J Clin Oncol 2006; 24(5)762–768
  • Angelopoulou K., Rosen B., Stratis M., Yu H., Solomou M., Diamandis E. P. Circulating antibodies against p53 protein in patients with ovarian carcinoma. Correlation with clinicopathologic features and survival. Cancer. 1996; 78(10)2146–2152
  • Lubin R., Schlichtholz B., Bengoufa D., et al. Analysis of p53 antibodies in patients with various cancers define B-cell epitopes of human p53: distribution on primary structure and exposure on protein surface. Cancer Res 1993; 53(24)5872–5876
  • Portefaix J. M., Fanutti C., Granier C., Crapez E., Perham R., Grenier J., Pau B., Del Rio M. Detection of anti-p53 antibodies by ELISA using p53 synthetic or phage-displayed peptides. J Immunol Methods 2002; 259(1–2)65–75
  • Changes in definitions of clinical staging for carcinoma of the cervix and ovary: International Federation of Gynecology and Obstetrics. Am J Obstet Gynecol 1987; 156(1)263–264
  • Gao R. J., Bao H. Z., Yang Q., Cong Q., Song J. N., Wang L. The presence of serum anti-p53 antibodies from patients with invasive ductal carcinoma of breast: correlation to other clinical and biological parameters. Breast Cancer Research and Treatment. 2005; 93(2)111–115
  • Vogl F. D., Stickeler E., Weyermann M., Vogl F D., Stickeler E., Weyermann M., Kohler T., Grill H J., Negri G., Kreienberg R., Runnebaum I. B. p53 autoantibodies in patients with primary ovarian cancer are associated with higher age, advanced stage and a higher proportion of p53-positive tumor cells. Oncology. 1999; 57(4)324–329
  • Green J. A., Robertson L. J., Campbell I. R., Jenkins J. Expression of the p53 gene and presence of serum autoantibodies in ovarian cancer: correlation with differentiation. Cancer Detect Prev. 1995; 19(2)151–155
  • Angelopoulou K., Rosen B., Stratis M., Yu H., Solomou M., Diamandis E. P. Circulating antibodies against p53 protein in patients with ovarian carcinoma. Correlation with clinicopathologic features and survival. Cancer. 1996; 78(10)2146–2152
  • Gadducci A., Ferdeghini M., Buttitta F., Cosio S., Fanucchi A., Annicchiarico C., Gagetti O., Bevilacqua G., Genazzani A. R. Assessment of the prognostic relevance of serum anti-p53 antibodies in epithelial ovarian cancer. Gynecol Oncol. 1999; 72(1)76–81
  • di Marzo Veronese F., Willis A. E., Boyer-Thompson C., Appella E., Perham R. N. Structural mimicry and enhanced immunogenicity of peptide epitopes displayed on filamentous bacteriophage. The V3 loop of HIV-1 gp120. J Mol Biol. 1994; 243(2)167–172
  • DePriest P. D., Gallion H. H., Pavlik E. J., Kryscio R. J., van Nagell J. R., Jr. Transvaginal sonography as a screening method for the detection of early ovarian cancer. Gynecol Oncol. 1997; 65(3)408–414
  • Vogl F. D., Frey M., Kreienberg R., Runnebaum I. B. Autoimmunity against p53 predicts invasive cancer with poor survival in patients with an ovarian mass. Br J Cancer. 2000; 83(10)1338–1343
  • Gadducci A., Ferdeghini M., Buttitta F., Cosio S., Fanucchi A., Annicchiarico C., Gagetti O., Bevilacqua G., Genazzani A. R. Assessment of the prognostic relevance of serum anti-p53 antibodies in epithelial ovarian cancer. Gynecol Oncol. 1999; 72(1)76–81
  • Fujita M., Enomoto T., Murata Y. Genetic alterations in ovarian carcinoma: with specific reference to histological subtypes. Mol Cell Endocrinol 2003; 202(1–2)97–99
  • Tarapore P., Fukasawa K. p53 mutation and mitotic infidelity. Cancer Invest. 2000; 18(2)148–155
  • Watanabe J., Nishiyama H., Kawanishi H., Ito M., Kamoto T., Ogawa O. Clinical evaluation of serum p53 antibodies in patients with upper urinary tract tumors. J Urol. 2005; 174(1)73–75
  • Limpaiboon T., Sripa B., Wongkham S., Bhudhisawasdi V., Chau-in S., Teerajetgul Y. Anti-p53 antibodies and p53 protein expression in cholangiocarcinoma. Hepatogastroenterology. 2004; 51(55)25–28
  • Gumus E., Erdamar S., Demirel G., Horasanli K., Kendirci M., Miroglu C. Association of positive serum anti-p53 antibodies with poor prognosis in bladder cancer patients. Int J Urol 2004; 11(12)1070–1077

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.